Autres langues Thiogenesis Therapeutics, Corp. OTC Markets

Actions

TTIPF

CA88410L1022

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets Autres places de cotation 17:27:52 05/06/2026			Varia. 5j.	Varia. 1 janv.
0,4200 ^USD	-6,67%		-.--%	-28,01%

13/07	Thiogenesis Therapeutics reçoit la désignation de maladie pédiatrique rare de la FDA pour le TTI-0102 dans le traitement du syndrome de Leigh	CI
13/07	Le traitement de Thiogenesis Therapeutics contre le syndrome de Leigh reçoit la désignation de maladie pédiatrique rare de la FDA	MT

Autres langues

13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation
13/07	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
17/06	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board
17/06	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors
17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
03/06	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
01/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
25/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement
11/05	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding
11/05	Thiogenesis Announces Non-Brokered Private Placement
30/04	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025
30/04	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt
16/04	Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
02/02	Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
02/02	Thiogenesis Therapeutics, Corp. Provides Program Update
23/01	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026
23/01	Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
13/01	Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
05/01	Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
09/12	Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th
26/11	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
24/11	Thiogenesis Therapeutics, Corp. Announces Plans to Initiate A Phase 3 Pivotal Clinical Trial of Its Lead Compound Tti-0102 for the Treatment of Nephropathic Cystinosis